SignalHF vs Zio AT ECG Monitoring System
AI Verdict
Choose SignalHF if…
Choose SignalHF if your primary objective is to proactively predict and prevent heart failure hospitalizations in patients with existing cardiac implantable electronic devices. This tool is ideal for care teams seeking an FDA-cleared AI algorithm to analyze CIED data, generate early alerts, and enable personalized interventions to reduce readmissions.
View SignalHF →Choose Zio AT ECG Monitoring System if…
Choose the Zio AT ECG Monitoring System if you require continuous, long-term ECG monitoring for the detection and diagnosis of cardiac arrhythmias. This wearable solution is best suited for identifying both symptomatic and asymptomatic cardiac events over an extended period, providing comprehensive reports for clinicians to guide treatment decisions.
View Zio AT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | SignalHF | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | SaaS | Cloud-based (data analytics and clinician portal) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio AT ECG Monitoring SystemTool B (Zio AT) offers a comprehensive usability experience for both patients and clinicians, featuring a wearable patch, a patient mobile app for symptom logging and education, and a clinician portal and app for management and interpretation. This patient-centric design, including at-home application, aims to simplify the monitoring process and improve patient compliance. Tool A (SignalHF) primarily focuses on clinician usability through a unified platform for centralizing CIED data and AI-driven alert management.
Clinical Value
TieBoth tools offer significant, yet distinct, clinical value. Tool A (SignalHF) provides FDA-cleared predictive AI for heart failure hospitalizations within 30 days, enabling early intervention and personalized care. Tool B (Zio AT) offers FDA-cleared, continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting, with studies showing high diagnostic yield and physician agreement. Their value lies in addressing different critical needs within cardiology: proactive prevention versus comprehensive diagnosis and monitoring.
Pricing & Value
TieBoth Tool A (SignalHF) and Tool B (Zio AT) require direct contact for pricing information, with no publicly disclosed details. While both are FDA-cleared and offer advanced AI-driven solutions in cardiology, making them premium services, the lack of transparent pricing prevents a direct comparison of their cost-effectiveness or value proposition.
Enterprise Readiness
SignalHFBoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and Business Associate Agreements (BAA). However, Tool A (SignalHF) explicitly highlights 'manufacturer-agnostic compatibility with various CIEDs' and a 'unified platform for centralizing cardiac implantable device data.' This feature suggests a potentially smoother integration into diverse hospital IT environments with existing fleets of cardiac devices from multiple manufacturers, giving it an edge in enterprise deployment.
Innovation
TieBoth tools showcase significant innovation in cardiac care. Tool A (SignalHF) innovates with its FDA-cleared predictive AI algorithm that forecasts heart failure hospitalizations, shifting care towards proactive prevention. Tool B (Zio AT) demonstrates innovation through its long-term wearable patch for continuous ECG recording combined with a deep-learned AI algorithm for comprehensive arrhythmia detection, improving upon traditional monitoring methods. Their innovative contributions are distinct but equally impactful in advancing cardiology.
Support & Docs
Zio AT ECG Monitoring SystemThe provided structured facts do not offer specific details on support or documentation for either tool. However, iRhythm Technologies (Tool B) is a larger, more established company with a broader market presence and explicitly mentions a dedicated team of patient advocates and financial assistance programs. This suggests a more extensive and structured support system for both clinicians and patients, including troubleshooting guides and patient resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | Zio AT ECG Monitoring System |
|---|---|---|
| Name | SignalHF | Zio AT ECG Monitoring System |
| Company | Implicity | iRhythm Technologies, Inc. |
| Primary Function | Predicts heart failure hospitalizations within 30 days | Continuous, AI-powered ECG monitoring for long-term arrhythmia detection |
| Key Technology / AI Focus | FDA-cleared AI algorithm for heart failure prediction | FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection |
| Device Type / Compatibility | Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs) | Wearable Zio AT patch |
| Monitoring / Prediction Scope | Predicts heart failure hospitalizations within 30 days | Continuous, uninterrupted ECG recording for up to 14 days |
| Alerts / Reporting | Generates automatic alerts for care teams based on risk scores | Comprehensive end-of-wear reports for clinicians |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring SignalHF or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.